ATOVAQUONE AND PROGUANIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Atovaquone And Proguanil Hydrochloride patents expire, and what generic alternatives are available?
Atovaquone And Proguanil Hydrochloride is a drug marketed by Glenmark Pharms Ltd and Mylan and is included in two NDAs.
The generic ingredient in ATOVAQUONE AND PROGUANIL HYDROCHLORIDE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atovaquone And Proguanil Hydrochloride
A generic version of ATOVAQUONE AND PROGUANIL HYDROCHLORIDE was approved as atovaquone; proguanil hydrochloride by GLENMARK PHARMS LTD on January 12th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
- What are the global sales for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
- What is Average Wholesale Price for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
Summary for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Clinical Trials: | 25 |
| Patent Applications: | 1 |
| DailyMed Link: | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Naval Medical Research Unit TWO (NAMRU-2) | Phase 4 |
| Naval Medical Research Center | Phase 4 |
| Naval Environmental Preventive Medicine Unit TWO (NEPMU-2) | Phase 4 |
See all ATOVAQUONE AND PROGUANIL HYDROCHLORIDE clinical trials
Pharmacology for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
| Drug Class | Antimalarial Antiprotozoal |
| Mechanism of Action | Dihydrofolate Reductase Inhibitors |
US Patents and Regulatory Information for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharms Ltd | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | atovaquone; proguanil hydrochloride | TABLET;ORAL | 091211-002 | Apr 6, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | atovaquone; proguanil hydrochloride | TABLET;ORAL | 202362-002 | May 27, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Glenmark Pharms Ltd | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | atovaquone; proguanil hydrochloride | TABLET;ORAL | 091211-001 | Jan 12, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | atovaquone; proguanil hydrochloride | TABLET;ORAL | 202362-001 | May 27, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
